MorphoSys AG
XETRA:MOR
MorphoSys AG
XETRA:MOR
Price:
66.65 EUR
0.83%
Market Closed
Updated:
May 4, 2024
Section:
Relative Value
The Relative Value of one
MOR
stock under the Base Case scenario is
36.99
EUR.
Compared to the current market price of 66.65 EUR,
MorphoSys AG
is
Overvalued by 44%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
MOR
Relative Value
Base Case
36.99
EUR
Overvaluation 44%
Valuation Multiples
Multiples Across Competitors
MOR Competitors Multiples
MorphoSys AG Competitors
MorphoSys AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
MorphoSys AG
XETRA:MOR
|
2.5B EUR | 10.5 | -13.2 | -9.3 | -8.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.1B USD | 5.3 | 60 | 12.9 | 19.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.4B USD | 6 | 25.1 | 18 | 27 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
103.5B USD | 7.9 | 26.2 | 17.6 | 19.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 10.5 | 28.6 | 22.8 | 23.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.2B AUD | 6.2 | 35.6 | 21.6 | 26.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.3B USD | 2.9 | 166 | 6.7 | 8.7 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
46.9B USD | 6.9 | -10 | -10.8 | -9.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
31.5B USD | 3.3 | 27 | 13.8 | 17.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
